prednisone has been researched along with navitoclax in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zinzani, PL | 1 |
| Ammatuna, E; de Jong, MRW; Langendonk, M; Nijland, M; Reitsma, B; van den Berg, A; van Meerten, T; Visser, L | 1 |
1 review(s) available for prednisone and navitoclax
| Article | Year |
|---|---|
Advances in management of follicular lymphoma.
Topics: Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Autografts; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Molecular Targeted Therapy; Neoplasm Staging; Prednisolone; Prednisone; Radioimmunotherapy; Rituximab; Sulfonamides; Vincristine | 2014 |
1 other study(ies) available for prednisone and navitoclax
| Article | Year |
|---|---|
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Myeloid Cell Leukemia Sequence 1 Protein; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Signal Transduction; Sulfonamides; Thiophenes; Treatment Outcome; Vincristine | 2019 |